NCT01955980View on ClinicalTrials.gov

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

October 27, 2015

Primary Completion Date

September 27, 2018

Study Completion Date

July 29, 2021

Conditions

Rhinosinusitis

Interventions

DRUG

Budesonide

Inhalation

DRUG

Budesonide

Nasal Spray

Trial Locations (3)

37099

University Göttingen, Göttingen

55131

UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz

81377

University Munich, Munich

Sponsors

Lead Sponsor

Pari Pharma GmbH

All Listed Sponsors

lead

Pari Pharma GmbH

INDUSTRY

NCT01955980 - Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis | Biotech Hunter | Biotech Hunter